Inmode Ltd (INMD) Stock Price, Quote & News

Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well a...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 909 6313

Website: www.inmodemd.com

Address:

Tavor Building, Sha’ar Yokneam PO Box 533, Yokne'am, Israel

findingthestock Jan. 28 at 4:49 PM

$INMD this will be a loss for so many if $16-17 is agreed upon We had a run up for the buyout rumors but now nothing and no further information or comments or unannounced events, SEC from INMODE…

0 · Reply

Remmers Jan. 28 at 3:24 PM

$INMD looks like the market is putting a fairly low probability on the likelihood of the sale going through.

0 · Reply

findingthestock Jan. 28 at 4:22 AM

$INMD doesn’t make sense how anyone could agree to $1.1 billion with no debt, $500 mill cash on hand. Biggest regret was not selling this when it went to 19s

1 · Reply

findingthestock Jan. 28 at 4:16 AM

$INMD

0 · Reply

Catvetty Jan. 28 at 4:08 AM

$INMD Why not even try dividend or spend whole cash before delist? I really dont understand the psychology here. Even Berkshire Hathaway will take a look when a deal is 3.5EV.

0 · Reply

findingthestock Jan. 27 at 11:54 PM

$INMD

0 · Reply

findingthestock Jan. 27 at 9:42 PM

$INMD “There are few signs of a near-term recovery as the company continues to face a challenging market environment for aesthetic capital equipment,” Eiber wrote, adding that other medical aesthetic companies including Syneron, Lumenis, Cynosure, Lutronic, and Alma Lasers have also been acquired by private equity funds over the last decade. Calcalist also reported that InMode had previously enlisted a bank to lead the sales process with the intention of settling on the highest bid. “We believe that taking [InMode] private makes sense given its combination of slow revenue growth and strong free cash flow,” Mike Matson, a medtech analyst at Needham & Co., wrote in a report. “Given [InMode’s] limited revenue growth, we think strategics are unlikely to be interested in acquiring it.”

0 · Reply

findingthestock Jan. 27 at 6:26 PM

$INMD Inmode can easily say they don’t comment on rumors They haven’t said a word Moshe will sell for $16 a share

0 · Reply

AshTradesFast Jan. 27 at 4:53 PM

$INMD mid-cap med-aesthetic, accumulation if consumer spend holds

0 · Reply

findingthestock Jan. 27 at 3:32 PM

$INMD Stock is sinking i think Moshe will try to justify a $16-17 a share buyout “premium” No SEC filing, no response to investors or comment Horrible

0 · Reply

InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

Dec 11, 2025, 6:26 PM EST - 6 weeks ago

InMode's Shares Are Too Cheap To Ignore: The Bottom May Be In

Nov 5, 2025, 12:51 PM EST - 2 months ago

InMode Ltd. (INMD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 3 months ago

InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

Nov 3, 2025, 8:05 AM EST - 3 months ago

InMode Appoints Michael Dennison as President of North America

Oct 30, 2025, 8:30 AM EDT - 3 months ago

InMode to Participate in Upcoming Investor Conferences

Oct 27, 2025, 2:07 PM EDT - 3 months ago

InMode: Discounted Valuation & Strong Fundamentals Make It A Buy

Oct 9, 2025, 7:00 AM EDT - 3 months ago

InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M

Sep 9, 2025, 8:15 AM EDT - 5 months ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

Sep 2, 2025, 8:30 AM EDT - 5 months ago

InMode to Present at Baird 2025 Global Healthcare Conference

Jul 30, 2025, 3:22 PM EDT - 6 months ago

InMode Ltd. (INMD) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 6 months ago

InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins

Jul 12, 2025, 8:08 AM EDT - 7 months ago

InMode: Margin Pressure, But Optionality Makes It Worth A Look

Jul 10, 2025, 7:00 AM EDT - 7 months ago

InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M

May 28, 2025, 8:30 AM EDT - 8 months ago

InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

May 9, 2025, 8:22 AM EDT - 9 months ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

May 7, 2025, 8:30 AM EDT - 9 months ago

InMode to Present at Upcoming Investor Conferences and Events

May 6, 2025, 8:03 AM EDT - 9 months ago

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

Apr 29, 2025, 7:00 AM EDT - 9 months ago

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

Apr 29, 2025, 1:52 AM EDT - 9 months ago

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Apr 28, 2025, 1:41 PM EDT - 9 months ago

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

Apr 28, 2025, 11:53 AM EDT - 9 months ago

InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 7:00 AM EDT - 9 months ago

InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

Apr 3, 2025, 4:26 AM EDT - 10 months ago

InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)

Mar 26, 2025, 8:30 AM EDT - 11 months ago

InMode to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 7:30 AM EST - 11 months ago

InMode Responds to Doma Perpetual's Letters

Mar 3, 2025, 8:30 AM EST - 11 months ago

InMode to Present at Upcoming Investor Conferences

Feb 10, 2025, 1:14 AM EST - 1 year ago

InMode: Plastic Surgery Boom, Cash Flow, And Cheap

Feb 6, 2025, 9:08 AM EST - 1 year ago

InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript

Feb 4, 2025, 7:00 AM EST - 1 year ago

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

Feb 3, 2025, 8:30 AM EST - 1 year ago

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

Jan 28, 2025, 9:32 AM EST - 1 year ago

InMode: A Clear Bargain With Unique Risks

Jan 16, 2025, 7:00 AM EST - 1 year ago

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

Jan 15, 2025, 8:05 AM EST - 1 year ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

Jan 10, 2025, 6:07 AM EST - 1 year ago

InMode: Clearly, I Was Too Optimistic (Rating Downgrade)

Jan 8, 2025, 7:00 AM EST - 1 year ago

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M

Dec 12, 2024, 1:17 AM EST - 1 year ago

InMode: Product Origination And Undervaluation Make The Stock A Buy

Nov 5, 2024, 9:43 AM EST - 1 year ago

InMode: $25/Share Is Closer Than You Think

Oct 31, 2024, 12:16 PM EDT - 1 year ago

InMode: A Deep Dive After Q3 Earnings

Oct 30, 2024, 11:33 AM EDT - 1 year ago

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 1 year ago

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

Oct 24, 2024, 7:03 AM EDT - 1 year ago

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

Oct 10, 2024, 7:00 AM EDT - 1 year ago

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

Oct 4, 2024, 8:00 AM EDT - 1 year ago

Stock Picks From Seeking Alpha's September 2024 New Analysts

AME CCL CRWD CUK DVN EGO EMR

Oct 1, 2024, 7:00 AM EDT - 1 year ago

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

Sep 19, 2024, 7:14 AM EDT - 1 year ago

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

Sep 10, 2024, 7:00 AM EDT - 1 year ago

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

Sep 6, 2024, 4:38 AM EDT - 1 year ago

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

Sep 4, 2024, 8:30 AM EDT - 1 year ago

InMode to Present at 2024 Baird Global Healthcare Conference

Aug 1, 2024, 11:19 AM EDT - 1 year ago

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

findingthestock Jan. 28 at 4:49 PM

$INMD this will be a loss for so many if $16-17 is agreed upon We had a run up for the buyout rumors but now nothing and no further information or comments or unannounced events, SEC from INMODE…

0 · Reply

Remmers Jan. 28 at 3:24 PM

$INMD looks like the market is putting a fairly low probability on the likelihood of the sale going through.

0 · Reply

findingthestock Jan. 28 at 4:22 AM

$INMD doesn’t make sense how anyone could agree to $1.1 billion with no debt, $500 mill cash on hand. Biggest regret was not selling this when it went to 19s

1 · Reply

findingthestock Jan. 28 at 4:16 AM

$INMD

0 · Reply

Catvetty Jan. 28 at 4:08 AM

$INMD Why not even try dividend or spend whole cash before delist? I really dont understand the psychology here. Even Berkshire Hathaway will take a look when a deal is 3.5EV.

0 · Reply

findingthestock Jan. 27 at 11:54 PM

$INMD

0 · Reply

findingthestock Jan. 27 at 9:42 PM

0 · Reply

findingthestock Jan. 27 at 6:26 PM

$INMD Inmode can easily say they don’t comment on rumors They haven’t said a word Moshe will sell for $16 a share

0 · Reply

AshTradesFast Jan. 27 at 4:53 PM

$INMD mid-cap med-aesthetic, accumulation if consumer spend holds

0 · Reply

findingthestock Jan. 27 at 3:32 PM

$INMD Stock is sinking i think Moshe will try to justify a $16-17 a share buyout “premium” No SEC filing, no response to investors or comment Horrible

0 · Reply

madjoker Jan. 27 at 1:41 PM

$INMD I’ve been asking chatgpt what typically happens after news leak and it says there’s some chance the offer price could be bumped due to shareholder pushback.

0 · Reply

findingthestock Jan. 27 at 12:55 PM

$INMD

0 · Reply

fgut88 Jan. 27 at 12:05 PM

$INMD It should be traded at 30-40.

0 · Reply

findingthestock Jan. 27 at 4:29 AM

$INMD Moshe will be kept on with the sale and company will be private and he will be compensated. The Israeli fund is interested in keeping the current management headed by founder Moshe Mizrahi, who has been running the company since its inception in 2007. Mizrahi holds 5.54% of the company's shares, worth about $50 million, and will be able to receive about $55-65 million upon completion of the deal. The company's CTO, Dr. Michael Kreindel, who founded it with Mizrahi and is responsible for some of its innovative developments, holds about 4.9% and will be able to receive about $50-55 million. Shareholders will lose a lot. Long term holders will get screwed.

0 · Reply

findingthestock Jan. 27 at 4:26 AM

$INMD At this stage, it appears that the foreign fund is leading the race, having offered a higher price. The Israeli fund is interested in keeping the current management headed by founder Moshe Mizrahi, who has been running the company since its inception in 2007. In contrast, the foreign group is likely to replace the management and reduce the company's activity in Israel.

0 · Reply

findingthestock Jan. 27 at 4:08 AM

$INMD Everyone agrees $17 share is ridiculous https://www.youtube.com/watch?v=1kwR2C7rpWc

0 · Reply

findingthestock Jan. 26 at 11:00 PM

$INMD Will Moshe negotiate and or get more bidders? Likely will just take $14-16 share price No shareholder return Been like that for years

1 · Reply

findingthestock Jan. 26 at 9:22 PM

$INMD No response back from investor relations

1 · Reply

topstockalerts Jan. 26 at 7:31 PM

$INMD Due for another run if this strength holds. Buyers continue to defend pullbacks. The trend is still intact.

0 · Reply

findingthestock Jan. 26 at 7:17 PM

$INMD there must be a SEC FILING of unannounced events

0 · Reply

mikesterz7 Jan. 26 at 7:15 PM

$INMD The company is set to go private after a $1.1 billion acquisition by a fund.

0 · Reply

Capitalism_daddy Jan. 26 at 6:53 PM

$INMD This is an outrageously low offer. There's 530 mil of pure cash in there. Then all else is a business model with 80% margins lol

0 · Reply

Market Cap	975.32M
Revenue (ttm)	394.82M
Net Income (ttm)	181.28M
EPS (ttm)	N/A
PE Ratio	9.96
Forward PE	N/A
Profit Margin	45.91%
Debt to Equity Ratio	0.00

Volume	812,400
Avg Vol	684,154
Day's Range	N/A - N/A
Shares Out	63.21M
Stochastic %K	70%
Beta	2.13
Analysts	Sell
Price Target	$16.60